Effect of recombinant human fibroblast growth factor-2 on bone formation in rabbit mandibular distraction models using beta-tricalcium phosphate.
This study was designed to evaluate the effect of recombinant human fibroblast growth factor-2 (rhFGF-2) on the amount and period of new bone formation in rabbit mandibular distraction models using beta-tricalcium phosphate (beta-TCP) as a bone graft substitute. Sixteen male Japanese White rabbits were divided into the following four experimental groups: 1, distraction alone; 2, distraction with beta-TCP granules; 3, distraction with rhFGF-2 (25 microg/50 microL) injected into beta-TCP granules; and 4, distraction with rhFGF-2 (100 microg/50 microL) injected into beta-TCP granules. The bones were harvested at 4 weeks after the operation and examined using soft radiography, micro-computed tomography (micro-CT), and peripheral quantitative computed tomography (pQCT). The dissected mandibles were stained using the Villanueva bone staining method, and the amount of new bone formed, bioresorption of beta-TCP, and new blood vessel formation were morphometrically calculated using bone histomorphometry. Radiopaque areas were observed more frequently in the distracted area of groups 3 and 4. Micro-CT analysis revealed partial new bone formation in the central region of the distracted area in groups 3 and 4. pQCT analysis revealed increased bone mineral density in groups 3 and 4. Histomorphometric analysis revealed increased newly formed bone and blood vessel areas in groups 3 and 4. In group 4, the number of osteoclasts around the beta-TCP granules had significantly increased. The present findings suggested that the combined use of rhFGF-2 and beta-TCP reduced the treatment period for distraction osteogenesis and accelerated the formation of a new high-quality bone.
Higuchi
Yusuke
Y
Oral and Maxillofacial Surgery, Department of Oral Restitution, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. yusuke-u.osur@tmd.ac.jp
Kabasawa
Yuhji
Y
Sato
Masaru
M
Kikuchi
Tsuyoshi
T
Aoki
Kazuhiro
K
Ohya
Keiichi
K
Maruoka
Yutaka
Y
Omura
Ken
K
D000818:Animals; D002130:Calcium Phosphates / Q000627:therapeutic use*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008334:Mandible / Q000033:anatomy & histology / Q000000981:diagnostic imaging / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects; D019857:Osteogenesis, Distraction / Q000379:methods; D011817:Rabbits; D011859:Radiography; D011994:Recombinant Proteins / Q000627:therapeutic use
D002130:Calcium Phosphates; D011994:Recombinant Proteins; C485817:beta-tricalcium phosphate; D016222:Fibroblast Growth Factor 2